According to a new report from Intel Market Research, the global Entereg (alvimopan) market was valued at USD 8.3 million in 2025 and is projected to reach USD 12.1 million by 2034, growing at a CAGR of 4.2% during the forecast period (2026-2034). This growth is driven by increasing surgical volumes and the adoption of enhanced recovery after surgery (ERAS) protocols worldwide.
? Download Sample Report: Entereg (alvimopan) Market - View in Detailed Research Report
What is Entereg (Alvimopan)?
Entereg (alvimopan), with CAS number 156053-89-3, is a peripherally acting μ-opioid receptor antagonist specifically designed to accelerate gastrointestinal recovery following bowel resection surgeries. Unlike traditional opioid treatments, Entereg targets opioid receptors in the gastrointestinal tract without interfering with central pain relief, making it a valuable tool in modern surgical care.
This comprehensive report examines all critical aspects of the Entereg market - from macro-level industry trends to micro-details including competitive dynamics, regulatory landscapes, and technological developments. The analysis provides actionable insights for:
- Pharmaceutical executives evaluating expansion strategies
- Healthcare providers optimizing postoperative care protocols
- Investors assessing market potential and risks
- Researchers pursuing next-generation gastrointestinal recovery solutions
Key Market Drivers
1. Rising Surgical Volumes and Focus on Enhanced Recovery
With over 50 million major abdominal surgeries performed annually worldwide, hospitals are increasingly adopting ERAS protocols to improve outcomes. Entereg has demonstrated the ability to reduce postoperative ileus-related hospital stays by an average of 1.5 days, generating cost savings of approximately $3,200 per patient case based on recent hospital data.
2. Advantages Over Conventional Treatments
Unlike systemic opioid antagonists that can compromise pain management, Entereg's peripheral action specifically targets gastrointestinal recovery while preserving central analgesic effects. This targeted mechanism positions it as a preferred option in modern multimodal analgesia approaches.
Market Challenges
- Restricted Distribution Program - The FDA-mandated Entereg Access Program limits prescribing to certified institutions, currently adopted by only 65% of eligible hospitals.
- Short Treatment Window - The 15-dose maximum regimen creates limited revenue potential compared to chronic medications.
- Established Competing Protocols - Many institutions continue relying on traditional opioid-sparing techniques despite Entereg's demonstrated advantages.
Emerging Opportunities
The Entereg market presents significant growth potential in developing healthcare markets where surgical capabilities are expanding. Key opportunity areas include:
- Emerging Economies - Countries like China and India could drive 30% of market expansion by 2028 as their healthcare infrastructure matures
- New Indications - Research into chronic opioid-induced bowel dysfunction could expand the addressable patient population by 1.8 million in the U.S. alone
- Minimally Invasive Surgery Adoption - Growing preference for laparoscopic procedures creates additional demand for effective recovery solutions
? Download Sample PDF: Entereg (alvimopan) Market - View in Detailed Research Report
Regional Market Insights
- North America: Leads global adoption with established reimbursement pathways and high surgeon awareness, accounting for 62% of current market revenue
- Europe: Displays steady growth through centralized procurement systems, though EMA usage restrictions create adoption barriers
- Asia-Pacific: Emerging as high-growth markets with Japan leading adoption and China showing accelerating interest
- Latin America/Middle East: Demonstrate selective adoption in premium healthcare institutions, though cost sensitivity remains a challenge
Market Segmentation
By Product Type
- 12 mg Capsules
- Generic Formulations
By Application
- Partial Bowel Resection
- Radical Cystectomy
- Other Abdominal Surgeries
By End User
- Hospitals
- Ambulatory Surgical Centers
- Specialty Clinics
By Region
- North America
- Europe
- Asia-Pacific
- Latin America
- Middle East & Africa
? Get Full Report Here: Entereg (alvimopan) Market - View Detailed Research Report
Competitive Landscape
Merck & Co. maintains market leadership through its 12 mg capsule formulation and controlled distribution network. However, the competitive landscape is evolving with:
- Teva Pharmaceutical and Sun Pharma developing generic alternatives
- Specialty pharma companies exploring novel formulations
- Distribution giants like Cardinal Health influencing market access
The report provides detailed competitive analysis of 15+ key players including their strategies, product pipelines, and geographical presence.
Report Value Proposition
This report delivers critical insights for stakeholders including:
- Market size projections through 2034 with segment-level forecasts
- Clinical trial landscape and regulatory developments
- Pricing analysis and reimbursement trends
- SWOT assessments of major market players
- Emerging technology and competitive threat evaluation
? Get Full Report Here: Entereg (alvimopan) Market - View Detailed Research Report
? Download Sample Report: Entereg (alvimopan) Market - View in Detailed Research Report
About Intel Market Research
Intel Market Research is a leading provider of strategic intelligence, offering actionable insights in biotechnology, pharmaceuticals, and healthcare infrastructure. Our research capabilities include:
- Real-time competitive benchmarking
- Global clinical trial pipeline monitoring
- Country-specific regulatory and pricing analysis
- Over 500+ healthcare reports annually
Trusted by Fortune 500 companies, our insights empower decision-makers to drive innovation with confidence.
? Website: https://www.intelmarketresearch.com
? Asia-Pacific: +91 9169164321
? LinkedIn: Follow Us
Comments